Pacira Biosciences, a leader in non-opioid pain management, actively advances its digital footprint to innovate therapeutic solutions and expand market reach. The company integrates advanced manufacturing process controls to scale production of its proprietary DepoFoam products, ensuring consistent quality and meeting growing demand. Pacira Biosciences also enhances its R&D and clinical operations through sophisticated data management for gene therapy development and comprehensive clinical trial execution.
These digital transformation efforts introduce critical dependencies on robust system integrations, precise data synchronization, and controlled workflow automation. Failures within these systems risk delays in drug development, inconsistencies in manufacturing, and inaccuracies in market access strategies. This page analyzes Pacira Biosciences' key initiatives, the operational challenges they present, and where sellers can engage effectively.
Pacira Biosciences Snapshot
Headquarters: Parsippany, NJ, United States
Number of employees: 829
Public or private: Public
Business model: B2B
Website: http://www.pacira.com
Pacira Biosciences ICP and Buying Roles
Pacira Biosciences sells to complex healthcare organizations, including large hospital networks, ambulatory surgical centers, and integrated delivery networks. They also engage with research institutions and clinical trial sites focused on advanced pain management therapies.
Who drives buying decisions
- Chief Information Officer (CIO) → Oversees enterprise-wide technology infrastructure and data security.
- VP of Manufacturing Operations → Manages production efficiency and quality control systems.
- Head of Clinical Development → Directs clinical trial execution and data integrity.
- VP of Market Access → Develops strategies for product reimbursement and payer relations.
Key Digital Transformation Initiatives at Pacira Biosciences (At a Glance)
- Automating EXPAREL manufacturing processes across 200-liter production suites.
- Modernizing clinical trial data capture and management systems for diverse studies.
- Integrating Real-World Evidence (RWE) into market access and commercial analytics platforms.
- Centralizing R&D data from gene therapy platforms into unified data repositories.
Where Pacira Biosciences’s Digital Transformation Creates Sales Opportunities
| Vendor Type | Where to Sell (DT Initiative + Challenge) | Buyer / Owner | Solution Approach |
|---|---|---|---|
| Manufacturing Operations Platforms | Automating EXPAREL manufacturing processes: calibration data discrepancies appear across equipment sensors. | VP of Operations, Director of Quality Control | Validate sensor data against production control system parameters. |
| Automating EXPAREL manufacturing processes: batches fail quality control checks due to inconsistent mixing. | Head of Manufacturing, Director of Quality | Monitor automated mixing parameters within validated ranges. | |
| Automating EXPAREL manufacturing processes: production scheduling conflicts arise when new lines integrate. | Head of Supply Chain, VP of Operations | Enforce seamless production scheduling across integrated manufacturing systems. | |
| Clinical Trial Management Systems | Modernizing clinical trial data capture: patient reported outcome data fails to sync from mobile devices. | VP of Clinical Operations, Head of Data Management | Route patient data from mobile devices into central EDC systems. |
| Modernizing clinical trial data capture: monitoring visits uncover discrepancies in the CTMS. | Chief Medical Officer, Head of Regulatory Affairs | Validate source documents against data records in the CTMS. | |
| Modernizing clinical trial data capture: regulatory submissions are delayed due to inconsistent patient identifiers. | Head of Data Management, Head of Regulatory Affairs | Standardize patient identifiers across clinical data reports. | |
| Data Integration & Analytics Platforms | Integrating RWE into market access: payer claims data does not align with internal patient outcome records. | Head of Market Access, VP of Commercial Operations | Validate payer claims data against commercial CRM patient records. |
| Integrating RWE into market access: data ingestion pipelines produce duplicate patient entries. | Head of Data Science, Chief Financial Officer | Detect and deduplicate patient entries during RWE data ingestion. | |
| Integrating RWE into market access: RWE dashboards display incorrect cost-benefit analyses. | Head of Data Science, Chief Financial Officer | Enforce consistent coding standards for RWE cost-benefit analysis. | |
| R&D Data Management Platforms | Centralizing R&D data from gene therapy platforms: genomic sequencing data fails to upload due to incompatible formats. | Head of R&D, Head of Bioinformatics | Standardize genomic data formats for ingestion into data lakes. |
| Centralizing R&D data from gene therapy platforms: experimental results do not link correctly in LIMS. | VP of Translational Medicine, Chief Scientific Officer | Validate experimental results against compound libraries in LIMS. | |
| Centralizing R&D data from gene therapy platforms: IP filings are delayed due to untracked research data. | Head of R&D, Chief Scientific Officer | Enforce accurate timestamping and versioning of research data in DMS. |
Identify when companies like Pacira Biosciences are in-market for your solutions.
Spot buying signals, find the right prospects, enrich your data, and reach out with relevant messaging at the right time.
What makes this Pacira Biosciences’s digital transformation unique
Pacira Biosciences’s digital transformation is distinctly driven by its focus on specialized pharmaceutical innovation, particularly in gene therapy and complex drug delivery. The company prioritizes enhancing manufacturing processes for its proprietary DepoFoam technology, a core differentiator, which demands highly specialized digital controls and validation. Furthermore, its market access strategy is deeply intertwined with integrating real-world evidence to navigate evolving reimbursement landscapes like the NOPAIN Act, requiring sophisticated data integration unique to the pharmaceutical industry.
Pacira Biosciences’s Digital Transformation: Operational Breakdown
DT Initiative 1: Manufacturing Process Automation & Optimization
What the company is doing
Pacira Biosciences is bringing enhanced, large-scale 200-liter manufacturing suites online. This initiative scales production capacity for EXPAREL. The company replaces older 45-liter facilities with these new advanced manufacturing lines.
Who owns this
- VP of Operations
- Head of Manufacturing
- Director of Quality Control
- Head of Supply Chain
Where It Fails
- Calibration data discrepancies appear between automated equipment sensors and production control systems.
- Batches fail quality control checks when automated mixing parameters drift from validated ranges.
- Production scheduling conflicts arise when new manufacturing lines integrate with existing supply chain planning.
Talk track
Noticed Pacira Biosciences is scaling EXPAREL manufacturing with new 200-liter production suites. Been looking at how some pharmaceutical teams are enforcing consistent calibration across automated systems instead of managing data discrepancies, can share what’s working if useful.
DT Initiative 2: Clinical Trial Data Management System Modernization
What the company is doing
Pacira Biosciences manages extensive clinical trials for multiple products, including EXPAREL, ZILRETTA, and the gene therapy PCRX-201. The company actively maintains observational registries such as IGOR. This work involves managing large volumes of patient and study data.
Who owns this
- VP of Clinical Operations
- Head of Data Management
- Chief Medical Officer
- Head of Regulatory Affairs
Where It Fails
- Patient reported outcome data fails to sync from mobile devices to the central electronic data capture (EDC) system.
- Investigator site monitoring visits uncover discrepancies between source documents and data recorded in the clinical trial management system (CTMS).
- Regulatory submissions are delayed when clinical data reports contain inconsistent patient identifiers across studies.
Talk track
Looks like Pacira Biosciences is managing a growing portfolio of clinical trials and registries. Been seeing how some biopharma teams are validating mobile-sourced patient data directly into their EDC systems instead of manually reconciling entries, happy to share what we’re seeing.
DT Initiative 3: Real-World Evidence (RWE) Data Integration & Analytics
What the company is doing
Pacira Biosciences integrates Real-World Evidence (RWE) into its market access and commercial strategies. This involves analyzing patient outcomes and cost data to demonstrate value to payers. The company utilizes RWE to support market expansion, particularly with the NOPAIN Act.
Who owns this
- Head of Market Access
- VP of Commercial Operations
- Head of Data Science
- Chief Financial Officer
Where It Fails
- Payer claims data does not align with internal patient outcome records in the commercial CRM system.
- Data ingestion pipelines for external RWE sources produce duplicate patient entries in the analytics platform.
- Real-world data dashboards display incorrect cost-benefit analyses due to disparate coding standards across datasets.
Talk track
Saw Pacira Biosciences is leveraging Real-World Evidence for market access strategies. Been looking at how some life sciences companies are standardizing external data coding before ingestion instead of correcting dashboard inaccuracies, can share what’s working if useful.
DT Initiative 4: R&D Data Management for Gene Therapy Platforms
What the company is doing
Pacira Biosciences develops novel gene therapies, such as PCRX-201, and integrates new gene therapy delivery platforms through acquisitions. This work generates complex genomic sequencing data and experimental results. The company requires robust systems for managing diverse research data.
Who owns this
- Head of R&D
- VP of Translational Medicine
- Head of Bioinformatics
- Chief Scientific Officer
Where It Fails
- Genomic sequencing data from research partners fails to upload to the R&D data lake due to incompatible file formats.
- Experimental results from in-vitro studies do not link correctly to associated compound libraries in the laboratory information management system (LIMS).
- Intellectual property filings are delayed when research data is not accurately timestamped and versioned in the document management system (DMS).
Talk track
Noticed Pacira Biosciences is advancing gene therapy platforms and R&D data management. Been looking at how some biotech firms are validating incoming genomic data formats before processing instead of troubleshooting failed uploads, happy to share what we’re seeing.
Who Should Target Pacira Biosciences Right Now
This account is relevant for:
- Manufacturing Process Orchestration Platforms
- Clinical Trial Management and Monitoring Solutions
- Real-World Evidence (RWE) Integration and Analytics Providers
- R&D Data Management and Bioinformatics Platforms
- Data Quality and Governance Solutions for Life Sciences
- Automated Regulatory Compliance Systems
Not a fit for:
- Generic HR and Payroll Software
- Basic E-commerce Website Builders
- Standalone Social Media Management Tools
- General Purpose CRM for B2C operations
- Consumer-facing mobile application development platforms
When Pacira Biosciences Is Worth Prioritizing
Prioritize if:
- You sell platforms for validating automated equipment sensor data against production system parameters.
- You sell solutions that route patient reported outcomes data seamlessly into central electronic data capture systems.
- You sell tools for standardizing external payer claims data to align with internal patient outcome records.
- You sell platforms for managing and standardizing genomic sequencing data ingestion from diverse research partners.
- You sell systems that enforce accurate timestamping and versioning of research data within document management systems.
Deprioritize if:
- Your solution does not address specific data quality or workflow automation breakdowns in pharmaceutical R&D, manufacturing, or clinical trials.
- Your product is limited to basic administrative functions without specialized capabilities for life sciences.
- Your offering is not built for complex, regulated data environments.
Who Can Sell to Pacira Biosciences Right Now
Manufacturing Process Orchestration Platforms
Siemens Digital Industries Software - This company offers a comprehensive portfolio of software for product lifecycle management, manufacturing operations management, and industrial automation.
Why they are relevant: Pacira Biosciences faces calibration data discrepancies between automated equipment sensors and production control systems within its enhanced manufacturing suites. Siemens' solutions can validate sensor data against production parameters, preventing inconsistencies and ensuring reliable product quality.
Emerson Process Management - This company provides automation technologies and engineering services, focusing on optimizing production, protecting personnel, and reducing emissions in process industries.
Why they are relevant: Pacira Biosciences experiences batches failing quality control checks due to automated mixing parameters drifting from validated ranges. Emerson's systems can monitor and enforce automated mixing parameters, maintaining consistency and preventing quality excursions.
Clinical Trial Management and Monitoring Solutions
Veeva Systems - This company provides cloud-based software for the global life sciences industry, including solutions for clinical, regulatory, quality, and commercial operations.
Why they are relevant: Pacira Biosciences encounters issues where patient reported outcome data fails to sync from mobile devices to its central electronic data capture system. Veeva's clinical solutions can route patient data from mobile devices directly into central EDC systems, ensuring data integrity and timely collection.
Medidata Solutions (a Dassault Systèmes company) - This company offers a unified platform for clinical development, providing solutions for trial planning, execution, management, and analytics.
Why they are relevant: Pacira Biosciences finds discrepancies between source documents and data recorded in the clinical trial management system (CTMS) during investigator site monitoring visits. Medidata's platform can validate source documents against CTMS records, preventing data mismatches and ensuring regulatory compliance.
Real-World Evidence (RWE) Integration and Analytics Providers
Datavant - This company connects health data to power the next generation of life-saving treatments, providing a secure and compliant platform for data exchange.
Why they are relevant: Pacira Biosciences deals with payer claims data not aligning with internal patient outcome records in its commercial CRM system. Datavant's data linking capabilities can validate payer claims data against commercial CRM patient records, creating a unified view for RWE analysis.
Flatiron Health - This company focuses on accelerating cancer research and improving patient care through its oncology-specific electronic health record (EHR) and real-world data platforms.
Why they are relevant: Pacira Biosciences' data ingestion pipelines for external RWE sources produce duplicate patient entries in its analytics platform. Flatiron's expertise in curating high-quality real-world oncology data includes mechanisms to detect and deduplicate patient entries during data ingestion.
R&D Data Management and Bioinformatics Platforms
Benchling - This company provides a cloud-based informatics platform for life sciences R&D, supporting capabilities across molecular biology, biologics, and other R&D workflows.
Why they are relevant: Pacira Biosciences experiences genomic sequencing data from research partners failing to upload to its R&D data lake due to incompatible file formats. Benchling's platform can standardize genomic data formats for ingestion, ensuring seamless data integration and accessibility for gene therapy research.
Thermo Fisher Scientific (Scientific Software and Informatics) - This company offers a range of laboratory information management systems (LIMS), chromatography data systems (CDS), and enterprise quality management software.
Why they are relevant: Pacira Biosciences finds that experimental results from in-vitro studies do not link correctly to associated compound libraries in its LIMS. Thermo Fisher's LIMS solutions can validate experimental results against compound libraries, ensuring accurate data association and accelerating research efforts.
Final Take
Pacira Biosciences scales its non-opioid pain management mission through advanced manufacturing automation and gene therapy R&D. Breakdowns are visible in manufacturing data integrity, clinical trial data synchronization, and RWE data consistency. This account is a strong fit for solutions that precisely control manufacturing processes, streamline clinical data flows, and ensure the accuracy of integrated real-world evidence.
Identify buying signals from digital transformation at your target companies and find those already in-market.
Find the right contacts and use tailored messages to reach out with context.